Cerebrolysin
- Category
- Brain & Cognition
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
Cerebrolysin is a mix of small peptides and amino acids from pig brain protein, used for cognitive decline, stroke, and brain injury. Human evidence is uneven: Alzheimer benefit is well supported, injury and stroke recovery only moderately so, and neuroplasticity claims remain speculative. A 2023 Cochrane review found no stroke mortality benefit and a possible increase in non-fatal serious adverse events, and it is contraindicated in severe renal impairment and status epilepticus, with caution required in other seizure disorders. Not FDA-approved in the US.
Read Full recordStudied uses & evidence
Studied uses(6)
Neuroprotection after acute brain injury
MediumHuman stroke and TBI trials show no clear survival benefit; strong animal neuroprotection data only.
Neuroplasticity enhancement
LowStrong animal evidence for enhanced plasticity; human data limited to indirect cognitive and BDNF signals.
Cognitive improvement in Alzheimer disease
HighMultiple placebo-controlled human trials show modest cognitive and global benefit, mostly short term.
Evidence limits
- Evidence Level
- Moderate
Strongest evidence for mild-to-moderate Alzheimer disease (6 RCTs, significant cognitive and global benefits). Promising but heterogeneous evidence for TBI (significant GOS improvement). Mixed evidence for acute ischemic stroke — a 2023 Cochrane review found no benefit for preventing all-cause mortality. Approved in 45+ countries based on available evidence.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Severe renal impairment
AbsoluteContains amino acid fragments that require renal clearance.
Epilepsy
HighNeurotrophic effects may lower seizure threshold. Use with caution in epilepsy.
General cautions
Pregnancy
HighAvoid during pregnancy unless clinically required. Animal reproductive studies found no evidence of reproductive toxicity; adequate human pregnancy safety is unestablished.
Risk summary(9)
Risks = level of concern: High · Moderate · Low · Theoretical
Not FDA-approved — limited regulatory oversight in the US
HighThe 2023 Cochrane review found no mortality benefit and a possible increase in non-fatal serious adverse events after acute ischemic stroke.
ModerateContraindicated in epilepsy — may lower seizure threshold
ModerateContraindicated in severe renal impairment.
ModerateContraindicated in hypersensitivity to porcine-derived biological products
ModerateCommon adverse effects: vertigo, agitation, feeling hot, headache, nausea, sweating (generally mild and transient)
LowPorcine-derived product carries theoretical risk of allergic reactions or prion concerns (though no cases documented)
TheoreticalHeterogeneous clinical evidence — stroke benefit remains controversial despite widespread international use
HighLack of standardization concerns: as a biological peptide mixture, batch-to-batch consistency may vary
Low
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.